Senseonics Holdings Inc (NYSEAMERICAN:SENS) has received an average rating of “Hold” from the six brokerages that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $6.00.
Separately, Zacks Investment Research lowered shares of Senseonics from a “hold” rating to a “sell” rating in a report on Saturday, May 11th.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace North America L.P. acquired a new stake in shares of Senseonics in the 1st quarter worth about $118,000. Marshall Wace LLP acquired a new stake in shares of Senseonics in the 1st quarter worth about $272,000. Sio Capital Management LLC raised its holdings in shares of Senseonics by 15.6% in the 1st quarter. Sio Capital Management LLC now owns 554,858 shares of the company’s stock worth $1,359,000 after acquiring an additional 75,000 shares during the last quarter. Man Group plc raised its holdings in shares of Senseonics by 83.3% in the 1st quarter. Man Group plc now owns 68,200 shares of the company’s stock worth $167,000 after acquiring an additional 31,000 shares during the last quarter. Finally, Jefferies Group LLC acquired a new stake in shares of Senseonics in the 1st quarter worth about $125,000. Institutional investors own 30.66% of the company’s stock.
Shares of NYSEAMERICAN SENS traded down $0.13 during trading on Friday, hitting $2.00. 1,560,580 shares of the company traded hands, compared to its average volume of 1,690,900. Senseonics has a fifty-two week low of $1.74 and a fifty-two week high of $5.29.
Senseonics (NYSEAMERICAN:SENS) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.05). The firm had revenue of $3.42 million for the quarter, compared to analysts’ expectations of $4.05 million.
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Featured Story: How does new data get added to a blockchain?
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.